{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:45:10Z","timestamp":1785267910105,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003969","name":"Iranian Ministry of Health and Medical Education","doi-asserted-by":"crossref","award":["700\/107"],"award-info":[{"award-number":["700\/107"]}],"id":[{"id":"10.13039\/501100003969","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"crossref","award":["910210"],"award-info":[{"award-number":["910210"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Polypharmacy in patients with cardiovascular diseases (CVDs) has been linked to several adverse outcomes. This study aimed to investigate the pattern of medication use and prevalence of polypharmacy among CVDs patients in Iran.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>We used the baseline data of the Pars cohort study (PCS). The participants were asked to bring their medication bags; then, the medications were classified using the Anatomical Therapeutic Chemical classification. Polypharmacy was defined as using five or more medications concurrently. Poisson regression modeling was applied. The adjusted prevalence ratios (PR) and its 95% confidence interval (CI) were estimated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Totally, 9262 participants were enrolled in the PCS, of whom 961 had CVDs. The prevalence of polypharmacy in participants with and without CVDs was 38.9% and 7.1%, respectively. The highest prevalence of polypharmacy (51.5%) was among obese patients. Abnormal waist-hip ratio (PR: 2.79; 95% CI 1.57\u20134.94), high socioeconomic status (PR: 1.65; 95% CI 1.07\u20132.54), tobacco-smoking (PR: 1.35; 95% CI 1.00\u20131.81), patients with more than three co-morbidities (PR: 1.41; 95% CI 1.30\u20131.53), high physical activity (PR: 0.66; 95% CI 0.45\u20130.95), use of opiate ever (PR: 0.46; 95% CI 0.26\u20130.82), and healthy overweight subjects (PR: 0.22; 95% CI 0.12\u20130.39) were associated with polypharmacy. Cardiovascular drugs (76.1%), drugs acting on blood and blood-forming organs (50.4%), and alimentary tract and metabolism drugs (33.9%) were the most frequently used drugs. Agents acting on the renin-angiotensin system were the mostly used cardiovascular system drugs among men and those above 60\u00a0years old, while beta-blocking agents were mostly prevalent among cardiovascular system drugs in women with CVDs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Given the high prevalence of polypharmacy among CVDs patients, and subsequent complications, programs to educate both physicians and patients to prevent this issue is crucial.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-022-02872-7","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T11:03:04Z","timestamp":1665054184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Population-based pattern of medication use and prevalence of polypharmacy among patients with cardiovascular diseases: results of the Pars cohort study from Iran"],"prefix":"10.1186","volume":"22","author":[{"given":"Pooran","family":"Mohsenzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ardekani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Poustchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Reza","family":"Abdipour Mehrian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Bazrafshan Drissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Rahimian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erfan","family":"Taherifard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Nabavizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"kamalipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Mesgarpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Malekzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Molavi Vardanjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"issue":"5","key":"2872_CR1","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/geront\/gnz102","volume":"60","author":"RM Gyasi","year":"2019","unstructured":"Gyasi RM, Phillips DR. Aging and the rising burden of noncommunicable diseases in sub-Saharan Africa and other low- and middle-income countries: a call for holistic action. Gerontologist. 2019;60(5):806\u201311.","journal-title":"Gerontologist"},{"issue":"20","key":"2872_CR2","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1016\/j.jacc.2019.10.009","volume":"74","author":"GA Mensah","year":"2019","unstructured":"Mensah GA, Roth GA, Fuster V. The global burden of cardiovascular diseases and risk factors: 2020 and beyond. J Am Coll Cardiol. 2019;74(20):2529\u201332.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2872_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/1753944718764588","volume":"12","author":"P L\u00f3pez-Jaramillo","year":"2018","unstructured":"L\u00f3pez-Jaramillo P, Gonz\u00e1lez-G\u00f3mez S, Zarate-Bernal D, Serrano A, Atuesta L, Clausen C, et al. Polypill: an affordable strategy for cardiovascular disease prevention in low\u2013medium-income countries. Ther Adv Cardiovasc Dis. 2018;12(6):169\u201374.","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"2","key":"2872_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.hfc.2013.12.001","volume":"10","author":"TG von Lueder","year":"2014","unstructured":"von Lueder TG, Atar D. Comorbidities and polypharmacy. Heart Fail Clin. 2014;10(2):367\u201372.","journal-title":"Heart Fail Clin"},{"key":"2872_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/10408363.2019.1678568","author":"CN Sharp","year":"2019","unstructured":"Sharp CN, Linder MW, Valdes R Jr. Polypharmacy: a healthcare conundrum with a pharmacogenetic solution. Crit Rev Clin Lab Sci. 2019. https:\/\/doi.org\/10.1080\/10408363.2019.1678568.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"Spec No","key":"2872_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.12927\/hcq..17669","volume":"8","author":"LK Taylor","year":"2005","unstructured":"Taylor LK, Kawasumi Y, Bartlett G, Tamblyn R. Inappropriate prescribing practices: the challenge and opportunity for patient safety. Healthc Q. 2005;8(Spec No):81\u20135.","journal-title":"Healthc Q"},{"issue":"6","key":"2872_CR7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.5001\/omj.2016.85","volume":"31","author":"A Al-Hashar","year":"2016","unstructured":"Al-Hashar A, Al Sinawi H, Al Mahrizi A, Al-Hatrushi M. Prevalence and covariates of polypharmacy in elderly patients on discharge from a tertiary care hospital in Oman. Oman Med J. 2016;31(6):421.","journal-title":"Oman Med J"},{"issue":"12","key":"2872_CR8","first-page":"53","volume":"2","author":"MM Al-Amin","year":"2012","unstructured":"Al-Amin MM, Zinchenko A, Rana MS, Uddin MMN, Pervin MS. Study on polypharmacy in patients with cardiovascular diseases. J Appl Pharm Sci. 2012;2(12):53.","journal-title":"J Appl Pharm Sci"},{"issue":"6","key":"2872_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234000","volume":"15","author":"YG Tefera","year":"2020","unstructured":"Tefera YG, Alemayehu M, Mekonnen GB. Prevalence and determinants of polypharmacy in cardiovascular patients attending outpatient clinic in Ethiopia University Hospital. PLoS ONE. 2020;15(6): e0234000.","journal-title":"PLoS ONE"},{"issue":"8","key":"2872_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255642","volume":"16","author":"EH Young","year":"2021","unstructured":"Young EH, Pan S, Yap AG, Reveles KR, Bhakta K. Polypharmacy prevalence in older adults seen in United States physician offices from 2009 to 2016. PLoS ONE. 2021;16(8): e0255642.","journal-title":"PLoS ONE"},{"key":"2872_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2147\/CLEP.S153458","volume":"10","author":"L Morin","year":"2018","unstructured":"Morin L, Johnell K, Laroche ML, Fastbom J, Wastesson JW. The epidemiology of polypharmacy in older adults: register-based prospective cohort study. Clin Epidemiol. 2018;10:289\u201398.","journal-title":"Clin Epidemiol"},{"key":"2872_CR12","doi-asserted-by":"publisher","first-page":"204209862093374","DOI":"10.1177\/2042098620933741","volume":"11","author":"M Khezrian","year":"2020","unstructured":"Khezrian M, McNeil CJ, Murray AD, Myint PK. An overview of prevalence, determinants and health outcomes of polypharmacy. Ther Adv Drug Saf. 2020;11:2042098620933741.","journal-title":"Ther Adv Drug Saf"},{"issue":"9","key":"2872_CR13","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00228-017-2288-1","volume":"73","author":"N Abolhassani","year":"2017","unstructured":"Abolhassani N, Castioni J, Marques-Vidal P, Vollenweider P, Waeber G. Determinants of change in polypharmacy status in Switzerland: the population-based CoLaus study. Eur J Clin Pharmacol. 2017;73(9):1187\u201394.","journal-title":"Eur J Clin Pharmacol"},{"key":"2872_CR14","doi-asserted-by":"publisher","first-page":"e200077","DOI":"10.1590\/1980-549720200077","volume":"23","author":"IR Silva","year":"2020","unstructured":"Silva IR, Gon\u00e7alves LG, Chor D, Fonseca M, Mengue SS, Acurcio FA, et al. Polypharmacy, socioeconomic indicators and number of diseases: results from ELSA-Brasil. Rev Bras de Epidemiol. 2020;23:e200077.","journal-title":"Rev Bras de Epidemiol"},{"issue":"12","key":"2872_CR15","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1080\/14740338.2018.1546841","volume":"17","author":"JW Wastesson","year":"2018","unstructured":"Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf. 2018;17(12):1185\u201396.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"2872_CR16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/fampra\/cms070","volume":"30","author":"D Koper","year":"2013","unstructured":"Koper D, Kamenski G, Flamm M, B\u00f6hmdorfer B, S\u00f6nnichsen A. Frequency of medication errors in primary care patients with polypharmacy. Fam Pract. 2013;30(3):313\u20139.","journal-title":"Fam Pract"},{"issue":"2","key":"2872_CR17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s11096-020-01028-x","volume":"42","author":"MV Lum","year":"2020","unstructured":"Lum MV, Cheung MYS, Harris DR, Sakakibara BM. A scoping review of polypharmacy interventions in patients with stroke, heart disease and diabetes. Int J Clin Pharm. 2020;42(2):378\u201392.","journal-title":"Int J Clin Pharm"},{"issue":"3","key":"2872_CR18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00038-016-0848-2","volume":"62","author":"A Gandomkar","year":"2017","unstructured":"Gandomkar A, Poustchi H, Moini M, Moghadami M, Imanieh H, Fattahi MR, et al. Pars cohort study of non-communicable diseases in Iran: protocol and preliminary results. Int J Public Health. 2017;62(3):397\u2013406.","journal-title":"Int J Public Health"},{"issue":"1","key":"2872_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230.","journal-title":"BMC Geriatr"},{"key":"2872_CR20","unstructured":"WHO. Anatomical Therapeutic Chemical (ATC) Classification [Available from: https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/atc-classification."},{"key":"2872_CR21","first-page":"2011","volume":"8\u201311","author":"World Health Organization","year":"2008","unstructured":"World Health Organization . Waist circumference and waist-hip ratio: report of a WHO expert consultation. Geneva. 2008;8\u201311:2011.","journal-title":"Geneva"},{"issue":"16","key":"2872_CR22","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KG Alberti","year":"2009","unstructured":"Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120(16):1640\u20135.","journal-title":"Circulation"},{"key":"2872_CR23","first-page":"1073","volume":"18","author":"MHB Moghaddam","year":"2012","unstructured":"Moghaddam MHB, Aghdam F, Asghari Jafarabadi M, Allahverdipour H, Nikookheslat S, Safarpour S. The Iranian Version of International Physical Activity Questionnaire (IPAQ) in Iran: content and construct validity, factor structure, internal consistency and stability. World Appl Sci J. 2012;18:1073\u201380.","journal-title":"World Appl Sci J"},{"issue":"2","key":"2872_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.15171\/mejdd.2018.94","volume":"10","author":"P Moezi","year":"2018","unstructured":"Moezi P, Salehi A, Molavi H, Poustchi H, Gandomkar A, Imanieh MH, et al. Prevalence of chronic constipation and its associated factors in pars cohort study: a study of 9000 adults in Southern Iran. Middle East J Dig Dis. 2018;10(2):75\u201383.","journal-title":"Middle East J Dig Dis"},{"issue":"6","key":"2872_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234386","volume":"15","author":"A Al-Dahshan","year":"2020","unstructured":"Al-Dahshan A, Al-Kubiasi N, Al-Zaidan M, Saeed W, Kehyayan V, Bougmiza I. Prevalence of polypharmacy and the association with non-communicable diseases in Qatari elderly patients attending primary healthcare centers: a cross-sectional study. PLoS ONE. 2020;15(6): e0234386.","journal-title":"PLoS ONE"},{"issue":"1","key":"2872_CR26","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1186\/s12913-017-2793-z","volume":"17","author":"J Castioni","year":"2017","unstructured":"Castioni J, Marques-Vidal P, Abolhassani N, Vollenweider P, Waeber G. Prevalence and determinants of polypharmacy in Switzerland: data from the CoLaus study. BMC Health Serv Res. 2017;17(1):840.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"2872_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12877-018-0795-2","volume":"18","author":"MJ Rawle","year":"2018","unstructured":"Rawle MJ, Richards M, Davis D, Kuh D. The prevalence and determinants of polypharmacy at age 69: a British birth cohort study. BMC Geriatr. 2018;18(1):118.","journal-title":"BMC Geriatr"},{"issue":"4","key":"2872_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232077","volume":"15","author":"A Aggarwal","year":"2020","unstructured":"Aggarwal A, Patel P, Lewison G, Ekzayez A, Coutts A, Fouad FM, et al. The Profile of Non-Communicable Disease (NCD) research in the Middle East and North Africa (MENA) region: analyzing the NCD burden, research outputs and international research collaboration. PLoS ONE. 2020;15(4): e0232077.","journal-title":"PLoS ONE"},{"key":"2872_CR29","unstructured":"Sechana K, Rashmi A. Assessment on prevalence of polypharmacy in geriatric patients with cardiovascular diseases. Int J Innov Sci Res Technol. 2020;5(6)."},{"issue":"1","key":"2872_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12875-016-0440-0","volume":"17","author":"AE Thompson","year":"2016","unstructured":"Thompson AE, Anisimowicz Y, Miedema B, Hogg W, Wodchis WP, Aubrey-Bassler K. The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC study. BMC Fam Pract. 2016;17(1):38.","journal-title":"BMC Fam Pract"},{"issue":"7","key":"2872_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2020.e04442","volume":"6","author":"S Ranjbaran","year":"2020","unstructured":"Ranjbaran S, Shojaeizadeh D, Dehdari T, Yaseri M, Shakibazadeh E. Determinants of medication adherence among Iranian patients with type 2 diabetes: an application of health action process approach. Heliyon. 2020;6(7): e04442.","journal-title":"Heliyon"},{"issue":"10076","key":"2872_CR32","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/S0140-6736(16)32381-9","volume":"389","author":"V Kontis","year":"2017","unstructured":"Kontis V, Bennett JE, Mathers CD, Li G, Foreman K, Ezzati M. Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble. The Lancet. 2017;389(10076):1323\u201335.","journal-title":"The Lancet"},{"issue":"1","key":"2872_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12875-018-0795-5","volume":"19","author":"A Rieckert","year":"2018","unstructured":"Rieckert A, Trampisch US, Klaa\u00dfen-Mielke R, Drewelow E, Esmail A, Johansson T, et al. Polypharmacy in older patients with chronic diseases: a cross-sectional analysis of factors associated with excessive polypharmacy. BMC Fam Pract. 2018;19(1):1\u20139.","journal-title":"BMC Fam Pract"},{"issue":"2","key":"2872_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-058333","volume":"12","author":"MJ Zibaeenezhad","year":"2022","unstructured":"Zibaeenezhad MJ, Sayadi M, Karimi-Akhormeh A, Ardekani A, Parsa N, Razeghian-Jahromi I. Potential of four definitions of metabolic syndrome to discriminate individuals with different 10-year cardiovascular disease risk scores: a cross-sectional analysis of an Iranian cohort. BMJ Open. 2022;12(2): e058333.","journal-title":"BMJ Open"},{"key":"2872_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fphar.2013.00091","volume":"4","author":"P Kardas","year":"2013","unstructured":"Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol. 2013;4:91.","journal-title":"Front Pharmacol"},{"issue":"9","key":"2872_CR36","doi-asserted-by":"publisher","first-page":"657","DOI":"10.34172\/aim.2021.94","volume":"24","author":"M Azadi","year":"2021","unstructured":"Azadi M, Kamalipour A, Molavi Vardanjani H, Poustchi H, Taherifard E, Sharifi MH, et al. Prevalence, pattern, and correlates of polypharmacy among Iranian Type II diabetic patients: results from pars cohort study. Arch Iran Med. 2021;24(9):657\u201364.","journal-title":"Arch Iran Med"},{"issue":"4","key":"2872_CR37","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/ehjcvp\/pvz014","volume":"5","author":"OI Woudstra","year":"2019","unstructured":"Woudstra OI, Kuijpers JM, Meijboom FJ, Post MC, Jongbloed MRM, Duijnhouwer AL, et al. High burden of drug therapy in adult congenital heart disease: polypharmacy as marker of morbidity and mortality. Eur Heart J Cardiovasc Pharmacother. 2019;5(4):216\u201325.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"2872_CR38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2174\/1871525715666170529093442","volume":"15","author":"M Abolbashari","year":"2017","unstructured":"Abolbashari M, Macaulay TE, Whayne TF, Mukherjee D, Saha S. Polypharmacy in cardiovascular medicine: problems and promises! Cardiovasc Hematol Agents Med Chem. 2017;15(1):31\u20139.","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"issue":"4","key":"2872_CR39","first-page":"228","volume":"58","author":"A Chris-Olaiya","year":"2020","unstructured":"Chris-Olaiya A, Palmer W, Stancampiano F, Lacy B, Heckman M, Chirila R, et al. Medication use and polypharmacy in patients referred to a tertiary gastroenterology practice. Rom J Intern Med. 2020;58(4):228\u201332.","journal-title":"Rom J Intern Med"},{"issue":"4","key":"2872_CR40","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s40292-015-0120-5","volume":"22","author":"C Borghi","year":"2015","unstructured":"Borghi C, Rossi F, Force ST, Force SIFT. Role of the renin-angiotensin-aldosterone system and its pharmacological inhibitors in cardiovascular diseases: complex and critical issues. High Blood Press Cardiovasc Prev. 2015;22(4):429\u201344.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"10","key":"2872_CR41","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.rec.2019.04.014","volume":"72","author":"J Mart\u00ednez-Milla","year":"2019","unstructured":"Mart\u00ednez-Milla J, Raposeiras-Roub\u00edn S, Pascual-Figal DA, Ib\u00e1\u00f1ez B. Role of beta-blockers in cardiovascular disease in 2019. Rev Espa\u00f1ola de Cardiol (English Edition). 2019;72(10):844\u201352.","journal-title":"Rev Espa\u00f1ola de Cardiol (English Edition)"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02872-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-022-02872-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02872-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T11:03:49Z","timestamp":1665054229000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-022-02872-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2872"],"URL":"https:\/\/doi.org\/10.1186\/s12872-022-02872-7","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"assertion":[{"value":"21 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and accepted by the Ethics Committees of Shiraz University of Medical Sciences (IR.SUMS.MED.REC.1401.263). Informed consent was obtained from all subjects or their legal guardian(s). All methods were carried out in accordance with relevant guidelines and regulations or declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"435"}}